Vestmark Advisory Solutions Inc. Buys 259,669 Shares of CRISPR Therapeutics AG $CRSP

Vestmark Advisory Solutions Inc. raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 115.3% in the 2nd quarter, HoldingsChannel reports. The fund owned 484,975 shares of the company’s stock after purchasing an additional 259,669 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in CRISPR Therapeutics were worth $23,589,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Bank of New York Mellon Corp increased its holdings in CRISPR Therapeutics by 1.5% in the 1st quarter. Bank of New York Mellon Corp now owns 77,702 shares of the company’s stock valued at $2,644,000 after buying an additional 1,133 shares during the period. Envestnet Asset Management Inc. grew its stake in shares of CRISPR Therapeutics by 21.5% in the 1st quarter. Envestnet Asset Management Inc. now owns 68,058 shares of the company’s stock valued at $2,316,000 after purchasing an additional 12,025 shares during the period. Axxcess Wealth Management LLC raised its holdings in shares of CRISPR Therapeutics by 4.0% in the 1st quarter. Axxcess Wealth Management LLC now owns 10,309 shares of the company’s stock worth $351,000 after buying an additional 393 shares in the last quarter. Leavell Investment Management Inc. bought a new position in shares of CRISPR Therapeutics during the 1st quarter worth approximately $340,000. Finally, Cerity Partners LLC acquired a new stake in CRISPR Therapeutics in the 1st quarter valued at $216,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 50,895 shares of the company’s stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $67.91, for a total value of $3,456,279.45. Following the completion of the sale, the chief executive officer owned 254,201 shares of the company’s stock, valued at approximately $17,262,789.91. This represents a 16.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 1,076 shares of the business’s stock in a transaction on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total transaction of $71,661.60. Following the completion of the transaction, the general counsel directly owned 83,402 shares of the company’s stock, valued at $5,554,573.20. This trade represents a 1.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 56,213 shares of company stock valued at $3,810,458 in the last ninety days. Insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Trading Down 4.4%

NASDAQ CRSP opened at $54.09 on Friday. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $78.48. The stock has a 50-day simple moving average of $62.86 and a 200 day simple moving average of $52.90. The company has a market capitalization of $4.92 billion, a PE ratio of -9.92 and a beta of 1.89.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.18. The firm had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $6.44 million. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.The company’s revenue was up 72.5% compared to the same quarter last year. During the same quarter last year, the business earned ($1.49) earnings per share. As a group, sell-side analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Royal Bank Of Canada raised their price objective on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the stock a “sector perform” rating in a report on Tuesday, August 5th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, September 23rd. Chardan Capital restated a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, August 5th. Barclays boosted their target price on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Wednesday, October 8th. Eleven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $69.06.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.